Sutro Biopharma reports FY2025 revenue $102.5M; cash runway extended into Q2 2028

SUTRO BIOPHARMA, INC.

Cash $141.4M at Dec 31, 2025; $110M underwritten offering extends runway into Q2 2028.
Revenue $102.5M (FY2025) vs $62.0M in 2024; R&D+G&A expenses reduced to $207.4M from $300.5M.
Terminated ATM Sales Agreement with Jefferies effective March 23, 2026.
STRO-004 Phase 1 dosed three cohorts; initial data mid-2026. STRO-227 IND submission on track for 2026.
Astellas TROP2 iADC program entered clinic; $10M milestone expected Q2 2026. Second program triggers $7.5M milestone.

item 1.02 item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

SUTRO BIOPHARMA, INC. reported financial results for the full year 2025.

Period: the full year 2025
Result: reported results

Exact text from the filing

On March 23, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SUTRO BIOPHARMA, INC. terminated Sales Agreement with Jefferies LLC (effective 2026-03-23).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Effective: 2026-03-23

Exact text from the filing

On March 23, 2026, the Company and Agent mutually agreed to terminate the Sales Agreement effective immediately as of March 23, 2026.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-119844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.